Renee Lamm, MD
Addiction Psychiatry · Myrtle Beach, SCNPI 1245214592
Payments from drug & device makers
Across 2,150 payments — averaging $589.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$419K
- Axsome Therapeutics, Inc.$306K
- AbbVie$201K
- Teva Pharmaceuticals USA, Inc.$176K
- Alkermes, Inc.$107K
- Vanda Pharmaceuticals Inc.$18K
- plus $40K from 24 others
What the payments were for
- Consulting fees$175,50814%
- Speaking & faculty fees$967,42976%
- Travel & lodging$91,3797%
- Food & beverage$32,3363%
- Education$1470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 581 | $419,498 |
| Axsome Therapeutics, Inc. | 417 | $305,850 |
| AbbVie(2 entities) | 430 | $200,722 |
| Teva Pharmaceuticals USA, Inc. | 234 | $175,814 |
| Alkermes, Inc. | 151 | $107,053 |
| Vanda Pharmaceuticals Inc. | 44 | $17,786 |
| Johnson & Johnson | 41 | $10,481 |
| Neurocrine Biosciences, Inc. | 32 | $9,965 |
| Takeda Pharmaceuticals U.S.A., Inc. | 35 | $7,713 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $6,568 |
| Sunovion Pharmaceuticals Inc. | 30 | $2,332 |
| Lundbeck LLC | 25 | $477 |
| Corium, LLC | 16 | $359 |
| E.r. Squibb & Sons, L.L.C. | 8 | $356 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $351 |
| Ironshore Pharmaceuticals Inc. | 14 | $336 |
| Tris Pharma Inc | 11 | $189 |
| Adlon Therapeutics L.p. | 10 | $173 |
| Indivior Inc. | 7 | $161 |
| Supernus Pharmaceuticals, Inc. | 4 | $111 |
| Avanir Pharmaceuticals, Inc. | 5 | $106 |
| Bausch Health US, LLC | 6 | $98 |
| Jazz Pharmaceuticals Inc. | 4 | $87 |
| Collegium Pharmaceutical, Inc. | 4 | $79 |
| Shire North American Group Inc | 2 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Neos Therapeutics, LP | 2 | $26 |
| Lilly USA, LLC | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$411,745
- Auvelity$299,064
- LYBALVI$262,728
- VRAYLAR$194,741
- AUSTEDO$78,936
- Austedo XR$78,566
- VIVITROL$39,275
- Fanapt$17,120
- UZEDY$15,071
- SPRAVATO$9,725
- INGREZZA$9,442
- TRINTELLIX$7,140
- CAPLYTA$5,891
- LATUDA$1,894
- ABILIFY MAINTENA$988
- COBENFY$123
- INVEGA TRINZA$119
- INVEGA SUSTENNA$119
How this compares
Too few addiction psychiatry providers in South Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 56 | $339,370 |
| IngrezzaValbenazine Tosylate | 30 | $243,283 |
| TrintellixVortioxetine Hydrobromide | 106 | $81,072 |
| RexultiBrexpiprazole | 28 | $39,347 |
| Invega SustennaPaliperidone Palmitate | 11 | $36,921 |
| AuvelityDextromethorphan Hbr/Bupropion | 33 | $33,126 |
| Lurasidone Hcl | 50 | $29,273 |
| VraylarCariprazine Hcl | 19 | $27,108 |
| VyvanseLisdexamfetamine Dimesylate | 33 | $14,882 |
| NamzaricMemantine Hcl/Donepezil Hcl | 19 | $11,117 |
| Duloxetine Hcl | 208 | $8,876 |
| Paliperidone ErPaliperidone | 11 | $7,151 |
| Lisdexamfetamine Dimesylate | 30 | $6,201 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 35 | $5,428 |
| FetzimaLevomilnacipran Hcl | 12 | $5,346 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $175,814 | $339,37056 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $9,965 | $243,28330 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $7,713 | $95,954139 claims |
| AbbVieVraylar, Namzaric, Fetzima | $200,722 | $43,57150 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $419,498 | $39,34728 claims |
| Johnson & JohnsonInvega Sustenna | $10,481 | $36,92111 claims |
| Axsome Therapeutics, Inc.Auvelity | $305,850 | $33,12633 claims |
| Lilly USA, LLCOlanzapine | $15 | $2,41681 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few addiction psychiatry providers in South Carolinaon file to place this against a meaningful peer group, so we don't.
Other addiction psychiatry in Myrtle Beach
- Raymond AntonCharleston$53K
- James WalkerGreer$100
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.